| The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. | lung, |
| Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. | breast, |
| Advanced cell- & animal imaging, expression profiling, stable siRNA-gene targeting, and TMAs of experimental and clinical samples indicate that activation of the BMI1 oncogene-associated PcG pathway plays an essential role in metastatic prostate cancer. | prostate, |
| Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. | prostate, |
| Bmi-1 and LMP1 down-regulate the ataxia telangiectasia-mutated (ATM) tumor suppressor and conclude that Bmi-1 contributes to LMP1-induced oncogenesis in Hodgkin lymphoma | lymphoma, |
| Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. | lymphoma, |
| Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. | breast, |
| Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. | liver, |
| BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia. | leukemia, |
| BMI1 is an oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia | leukemia, |
| Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. | lung, |
| Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. | glioma, |
| The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. | sarcoma, |
| Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. | esophageal, |
| Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. | liver, |
| Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. | colorectal, |
| Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway. | glioma, |
| BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer. | gastric, |
| Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. | lung, |
| Knockdown of the Bmi-1 oncogene inhibits cell proliferation and induces cell apoptosis and is involved in the decrease of Akt phosphorylation in the human breast carcinoma cell line MCF-7. | breast, |